

Source

HRSV (A) Fusion glycoprotein F0, His Tag (RSF-V52H6) is expressed from human 293 cells (HEK293).
Predicted N-terminus: Gln 26

Molecular Characterization

This protein carries a polyhistidine tag at the C-terminus
The protein has a calculated MW of 55.2 kDa. The protein migrates as 47-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per µg by the LAL method.

Purity

>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation

Lyophilized from 0.22 µm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.

Reconstitution


Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage

After reconstitution, this product is stable after storage at -70°C for 3 months.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:

- For long term storage, the product is stable for up to 3 years at -70°C from date of receipt;
- For short term storage, the product is stable for up to 12 months at 2-8°C from date of receipt.


SDS-PAGE




HRSV (A) Fusion glycoprotein F0, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA


SEC-MALS




The purity of HRSV (A) Fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) is more than 90% and the molecular weight of this protein is around 165-185 kDa verified by SEC-MALS.
[Report](#)




Immobilized HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) and HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 1 µg/mL (100 µL/well) can bind Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F) with a linear range of 0.1-4 ng/mL (QC tested).




Immobilized HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 1 µg/mL (100 µL/well) can bind Recombinant Human Anti-RSV Antibody (AM14) with a linear range of 0.004-0.25 µg/mL. HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) is verified not recognized by Recombinant Human Anti-RSV Antibody (AM14) (QC tested).



Immobilized HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 1 µg/mL (100 µL/well) can bind Recombinant Mouse Anti-RSV F Antibody (5C4) with a linear range of 0.004-0.25 µg/mL. HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) is verified not recognized by Recombinant Mouse Anti-RSV F Antibody (5C4) (Routinely tested).




Immobilized HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) and HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 1 µg/mL (100 µL/well) can bind Anti-RSV Fusion Protein Antibody (131-2A) with a linear range of 0.1-1 ng/mL (Routinely tested).



Immobilized HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 1 µg/mL (100 µL/well) can bind Recombinant Human Anti-RSV Antibody (D25) with a linear range of 0.1-2 ng/mL. HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) is verified not recognized by

Recombinant Human Anti-RSV Antibody (D25) in low concentration
(Routinely tested).



Immobilized HRSV (A) Post-fusion glycoprotein F0, His Tag (MALS verified)
(Cat. No. RSF-V52H6) at 2 µg/mL (100 µL/well) can bind Monoclonal Anti-RSV-F0 broadly Antibody, Mouse IgG1 (3B4) (Cat. No. RS0-Y161) with a linear range of 0.144-9.197 ng/mL (Routinely tested).

Background

Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation. Both states exhibit epitopes targeted by neutralizing antibodies, and post-fusion RSV F is being developed as a vaccine candidate.

Clinical and Translational Updates

Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.